DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2006/0140990 A1 Bortz Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2006/0140990 A1 Bortz Et Al US 2006O140990A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0140990 A1 Bortz et al. (43) Pub. Date: Jun. 29, 2006 (54) COMPOSITION FOR TOPICAL TREATMENT (60) Provisional application No. 60/507,138, filed on Oct. OF MIXED VAGINAL INFECTIONS 1, 2003. Provisional application No. 60/504,017, filed on Sep. 19, 2003. (75) Inventors: Jonathan Bortz, Saint Louis, MO (US); R. Saul Levinson, Chesterfield, Publication Classification MO (US); Mitchell Kirschner, St. (51) Int. Cl. Louis, MO (US); Robert C. Cuca, A61K 3 1/7034 (2006.01) Glen Carbon, IL (US) A6IR 9/00 (2006.01) Correspondence Address: (52) U.S. Cl. .............................................. 424/400: 514/35 HARNESS, DICKEY, & PIERCE, P.L.C (57) ABSTRACT 7700 BONHOMME, STE 400 ST. LOUIS, MO 63105 (US) A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively (73) Assignee: Drug Tech Corporation, Wilmington, comprising clindamycin or a pharmaceutically acceptable salt or ester thereof, and (b) an antifungal agent in an DE (US) antifungally effective amount, illustratively comprising (21) Appl. No.: 11/326,979 butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit (22) Filed: Jan. 5, 2006 dose amount to a Vulvovaginal Surface and has at least one nonlipoidal internal phase and at least one lipoidal external Related U.S. Application Data phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a Vulvovaginal (63) Continuation-in-part of application No. 10/944,416, Surface to treat a mixed bacterial vaginosis and Vulvovaginal filed on Sep. 20, 2004. candidiasis infection. US 2006/O 140990 A1 Jun. 29, 2006 COMPOSITION FOR TOPCAL TREATMENT OF increased susceptibility to viral infection including HIV and MIXED VAGINAL INFECTIONS HSV-2, and, in pregnant women, premature birth, preterm 0001. This application is a continuation-in-part of appli rupture of membranes, intra-amniotic fluid infection, pre cation Ser. No. 10/944,416, filed on Sep. 20, 2004, which term labor and postpartum endometritis. claims priority of provisional application Ser. No. 60/507, 0010 Bacterial and candidal infections can coexist. 138, filed on Oct. 1, 2003 and provisional application Ser. Mixed bacterial and candidal (herein “BV/VVC) infection No. 60/504,017, filed on Sep. 19, 2003. Each of the above occurs in up to about one-fifth of vaginitis cases. For cited applications is incorporated in its entirety herein by example, Redondo-Lopez et al. (1990), Sex. Transm. Dis. reference. 17(1):51-53, reported that in 132 episodes of symptomatic vaginitis in 35 patients with recurring symptoms, 15% were FIELD OF THE INVENTION found to involve a mixed BV/VVC infection. 0002 The present invention relates to pharmaceutical 0011. In another study, Ferris et al. (2002), Obstet. compositions suitable for vaginal delivery of an antifungal Gynecol. 99(3):419–425, reported that of 95 women who agent and an antibacterial agent. The invention further were about to treat themselves for VVC, 34% were con relates to therapeutic methods of use of Such compositions firmed to have VVC alone, 19% had BV alone, and 19% had in women having mixed fungal and bacterial infections of a mixed BV/VVC infection. the Vulvovaginal system. 0012. A significant problem is that such mixed infections BACKGROUND OF THE INVENTION are underdiagnosed, and self-medication or prescribed treat ment occurs as if for fungal or bacterial infection alone. Both 0003 Infective vaginitis covers a range of conditions fungi such as Candida albicans and bacteria Such as Gard involving microbial infection of the vagina, and inflamma merella vaginalis are opportunistic pathogens, therefore in tion associated therewith, that sometimes extends to the case of a mixed infection removal of one can lead to rapid Vulva. It accounts for an estimated 15 million physician population growth of the other. Thus, for example, a mixed office visits a year in the U.S., and with availability of BV/VVC infection treated topically only with an antifungal over-the-counter remedies particularly for candidal infec agent such as butoconazole can quickly become a serious tions, many additional cases are medicated without profes BV infection, which then requires follow-up antibacterial sional diagnosis. treatment, either as a further topical application or as sys temic (e.g., oral antibiotic) therapy. Implications of such 0004 Agents of infection implicated in vaginitis include: misdiagnosis can be nontrivial, especially considering the 0005 (a) fungi, more particularly yeasts, especially Can serious conditions to which BV can lead if untreated. dida spp. including one or more of C. albicans, C. dublin iensis, C. glabrata, C. kefir, C. krusei, C. lusitaniae, C. 0013 Thus a need exists in the art for a medicament and neoformans, C. parasilopsis and C. tropicalis, of which the method of use thereof that conveniently and effectively most common is C. albicans, treats mixed BV/VVC infections. 0006 (b) bacteria, commonly a variety of species includ 0014 U.S. Pat. No. 4,551,148 to Riley et al. proposes a ing one or more of Bacteroides spp., Gardnerella vaginalis, controlled release system for vaginal drug delivery, com Mobiluncus spp., Mycoplasma hominis and Peptostrepto prising unit cells having a nonlipoidal internal phase and a coccus spp., most commonly with G. vaginalis predominat lipoidal continuous external phase. An active agent is ing; and present at least in the internal phase. 0007 (c) protozoa, especially Trichomonas vaginalis. 0.015 U.S. Pat. No. 5.266,329 to Riley proposes such a vaginal delivery system having an antifungal imidazole, 0008 Candidal infections, herein referred to collectively exemplified by metronidazole, as the active agent. as vulvovaginal candidiasis (VVC), are the best known cause of vaginitis and are believed to affect about 75% of 0016 Thompson & Levinson (2002), Drug Delivery Sys women at least once during their lifetime. VVC is generally tems & Sciences 2(1), 17-19, describe a bioadhesive topical not sexually transmitted. Bacterial vaginosis (BV), a collec drug delivery system known therein as the VagiSite system tive term used herein for vaginal or Vulvovaginal conditions as a high internal phase ratio water-in-oil emulsion system, caused by bacterial infection, is generally considered a providing a delivery platform for administration of active sexually transmitted disease although other modes of trans drug entities in the vaginal cavity. They disclose that the mission can occur. Symptoms of VVC and BV include VagiSite system is incorporated in Gynazole-1(R) antifungal irritation (manifesting, for example, as redness, burning vaginal cream, which contains 2% by weight butoconazole and/or itching), dyspareunia and abnormal discharge, which nitrate. in the case of BV tends to have a fishy odor. Other diagnostic 0017 U.S. Patent Application Publication No. 2003/ criteria include a vaginal pH lower than about 4.7 in VVC, 0180366 of Kirschner et al. discloses a composition suitable or higher than about 4.7 in BV, and presence of "clue cells' for vaginal drug delivery, comprising an essentially pH (epithelial cells having a granular appearance) in BV. neutral emulsion having an internal water-soluble phase and 0009 VVC is typically a nuisance, often very troubling an external water-insoluble phase, wherein the internal to the patient but relatively rarely implicated in development phase comprises an acidic buffered phase comprising a drug, of more serious or life-threatening conditions. On the other which can illustratively be an antifingal agent or an anti hand, BV, if untreated, can lead to serious conditions. Such bacterial agent. Example I therein provides such a compo as cerviciitis, pelvic inflammatory disease, cervical dyspla sition comprising the antibacterial agent metronidazole in an sia, urinary tract infections, postoperative infections, amount of 0.75% by weight. Example II therein provides US 2006/O 140990 A1 Jun. 29, 2006 Such a composition comprising the antibacterial agent clin U.S. Patent Application Publication No. 2003/0180366, or damycin phosphate in an amount of 2.8% by weight. as further described herein. Such a water-in-oil emulsion can 0018 U.S. Pat. No. 5,055.303 to Riley describes a solid be presented in a Solid form, for example as a vaginal composition, for example a Suppository, comprising a water Suppository, or in a semi-solid form, for example as a in-oil emulsion that can carry an active agent. The compo vaginal cream, and has bioadhesive properties. sition is stated to be suitable for insertion into a body orifice 0029 A“vulvovaginal surface herein denotes any exter and to melt at body temperature to form a cream having nal or internal Surface of the female genitalia, including controlled release and bioadherent properties. mucosal Surfaces in the vaginal cavity and nonmucosal 0019 U.S. Patent Application Publication No. 2003/ Surfaces of the Vulva and immediately Surrounding areas of 0225,034 of Floros et al. mentions that, for treatment of skin. In some embodiments, the composition is more spe vaginitis, Surfactant lipids can be administered in conjunc cifically adapted for application to a vaginal mucosal Sur tion with one or more medications including antibiotics and face, and the external phase of the composition is bioadhe antifungals. Examples of antibiotics said to be suitable sive, i.e., mucoadhesive, to Such a surface. include amplicillin, ceftriaxone, clindamycin, metronidazole 0030. In one embodiment, the composition is formulated and tetracycline. Examples of antifungals said to be suitable as a bioadhesive vaginal delivery system as described by include miconazole, clotrimazole, econazole, butoconazole, Thompson & Levinson (2002), op. cit. under the name tioconazole and terconazole. VagiSite, or a vaginal delivery system Substantially equiva lent thereto, including as active agents an antibacterial agent SUMMARY OF THE INVENTION and an antifungal agent. 0020. There is now provided a pharmaceutical composi 0.031) International Patent Publication No.
Load more

Recommended publications
  • Diagnosis and Treatment of Tinea Versicolor Ronald Savin, MD New Haven, Connecticut
    ■ CLINICAL REVIEW Diagnosis and Treatment of Tinea Versicolor Ronald Savin, MD New Haven, Connecticut Tinea versicolor (pityriasis versicolor) is a common imidazole, has been used for years both orally and top­ superficial fungal infection of the stratum corneum. ically with great success, although it has not been Caused by the fungus Malassezia furfur, this chronical­ approved by the Food and Drug Administration for the ly recurring disease is most prevalent in the tropics but indication of tinea versicolor. Newer derivatives, such is also common in temperate climates. Treatments are as fluconazole and itraconazole, have recently been available and cure rates are high, although recurrences introduced. Side effects associated with these triazoles are common. Traditional topical agents such as seleni­ tend to be minor and low in incidence. Except for keto­ um sulfide are effective, but recurrence following treat­ conazole, oral antifungals carry a low risk of hepato- ment with these agents is likely and often rapid. toxicity. Currently, therapeutic interest is focused on synthetic Key Words: Tinea versicolor; pityriasis versicolor; anti­ “-azole” antifungal drugs, which interfere with the sterol fungal agents. metabolism of the infectious agent. Ketoconazole, an (J Fam Pract 1996; 43:127-132) ormal skin flora includes two morpho­ than formerly thought. In one study, children under logically discrete lipophilic yeasts: a age 14 represented nearly 5% of confirmed cases spherical form, Pityrosporum orbicu- of the disease.3 In many of these cases, the face lare, and an ovoid form, Pityrosporum was involved, a rare manifestation of the disease in ovale. Whether these are separate enti­ adults.1 The condition is most prevalent in tropical tiesN or different morphologic forms in the cell and semitropical areas, where up to 40% of some cycle of the same organism remains unclear.: In the populations are affected.
    [Show full text]
  • 4 Supplementary File
    Supplemental Material for High-throughput screening discovers anti-fibrotic properties of Haloperidol by hindering myofibroblast activation Michael Rehman1, Simone Vodret1, Luca Braga2, Corrado Guarnaccia3, Fulvio Celsi4, Giulia Rossetti5, Valentina Martinelli2, Tiziana Battini1, Carlin Long2, Kristina Vukusic1, Tea Kocijan1, Chiara Collesi2,6, Nadja Ring1, Natasa Skoko3, Mauro Giacca2,6, Giannino Del Sal7,8, Marco Confalonieri6, Marcello Raspa9, Alessandro Marcello10, Michael P. Myers11, Sergio Crovella3, Paolo Carloni5, Serena Zacchigna1,6 1Cardiovascular Biology, 2Molecular Medicine, 3Biotechnology Development, 10Molecular Virology, and 11Protein Networks Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 34149, Trieste, Italy 4Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy 5Computational Biomedicine Section, Institute of Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany 6Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy 7National Laboratory CIB, Area Science Park Padriciano, Trieste, 34149, Italy 8Department of Life Sciences, University of Trieste, Trieste, 34127, Italy 9Consiglio Nazionale delle Ricerche (IBCN), CNR-Campus International Development (EMMA- INFRAFRONTIER-IMPC), Rome, Italy This PDF file includes: Supplementary Methods Supplementary References Supplementary Figures with legends 1 – 18 Supplementary Tables with legends 1 – 5 Supplementary Movie legends 1, 2 Supplementary Methods Cell culture Primary murine fibroblasts were isolated from skin, lung, kidney and hearts of adult CD1, C57BL/6 or aSMA-RFP/COLL-EGFP mice (1) by mechanical and enzymatic tissue digestion. Briefly, tissue was chopped in small chunks that were digested using a mixture of enzymes (Miltenyi Biotec, 130- 098-305) for 1 hour at 37°C with mechanical dissociation followed by filtration through a 70 µm cell strainer and centrifugation.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Therapeutic Class Overview Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]
  • Therapeutic Drug Class
    BUREAU FOR MEDICAL SERVICES WEST VIRGINIA MEDICAID EFFECTIVE PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA 07/01/13 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL. Version 2013.3c Prior authorization for a non-preferred agent in any category will be given only if there has been a trial of the preferred brand/generic equivalent or preferred formulation of the active ingredient, at a therapeutic dose, that resulted in a partial response with a documented intolerance. Prior authorization of a non-preferred isomer, pro-drug, or metabolite will be considered with a trial of a preferred parent drug of the same chemical entity, at a therapeutic dose, that resulted in a partial response with documented intolerance or a previous trial and therapy failure, at a therapeutic dose, with a preferred drug of a different chemical entity indicated to treat the submitted diagnosis. (The required trial may be overridden when documented evidence is provided that the use of these preferred agent(s) would be medically contraindicated.) Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC drugs are not covered unless specified. PA criteria for non-preferred agents apply in addition to general Drug Utilization Review policy that is in effect for the entire pharmacy program, including, but not limited to, appropriate dosing, duplication of therapy, etc. The use of pharmaceutical samples will not be considered when evaluating the members’ medical condition or prior prescription history for drugs that require prior authorization.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Oxistat® (Oxiconazole) Prior Authorization Request Form DO NOT COPY for FUTURE USE
    OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations. Visit go.covermymeds.com/OptumRx to begin using this free service Oxistat® (oxiconazole) Prior Authorization Request Form DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY HAVE BARCODES. This form may be faxed to 844-403-1029. Member Information (required) Provider Information (required) Member Name: Provider Name: Insurance ID#: NPI#: Specialty: Date of Birth: Office Phone: Street Address: Office Fax: City: State: ZIP: Office Street Address: Phone: City: State: ZIP: Medication Information (required) Medication Name: Strength: Dosage Form: Directions for Use: Clinical Information (required) 1. Does the patient have a diagnosis of tinea infection (i.e., tinea pedis, cruris, corporis or versicolor)? ❑ Yes ❑ No 2. Has the patient experienced an inadequate treatment response, intolerance or contraindication to any of ❑ Yes ❑ No the following generic creams: terbinafine 1%, clotrimazole 1%, ketoconazole 2% or miconazole 1% or 2%? 3. Does the requested quantity exceed 120 units (grams or milliliters)? ❑ Yes ❑ No Information on this form is accurate as of this date. Prescriber’s Signature: Date: Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review? ________________________________________________________________________________________________________________ ________________________________________________________________________________________________________________
    [Show full text]
  • Oxistat Oxistat
    PRESCRIBING INFORMATION OXISTAT® (oxiconazole nitrate cream) Cream, 1%* OXISTAT® (oxiconazole nitrate lotion) Lotion, 1%* *Potency expressed as oxiconazole FOR TOPICAL DERMATOLOGIC USE ONLY— NOT FOR OPHTHALMIC OR INTRAVAGINAL USE DESCRIPTION OXISTAT Cream and Lotion formulations contain the antifungal active compound oxiconazole nitrate. Both formulations are for topical dermatologic use only. Chemically, oxiconazole nitrate is 2',4'-dichloro-2-imidazol-1-ylacetophenone (Z)-[0-(2,4- dichlorobenzyl)oxime], mononitrate. The compound has the empirical formula C18H13ON3Cl4•HNO3, a molecular weight of 492.15, and the following structural formula: Oxiconazole nitrate is a nearly white crystalline powder, soluble in methanol; sparingly soluble in ethanol, chloroform, and acetone; and very slightly soluble in water. OXISTAT Cream contains 10 mg of oxiconazole per gram of cream in a white to off-white, opaque cream base of purified water USP, white petrolatum USP, stearyl alcohol NF, propylene glycol USP, polysorbate 60 NF, cetyl alcohol NF, and benzoic acid USP 0.2% as a preservative. OXISTAT Lotion contains 10 mg of oxiconazole per gram of lotion in a white to off-white, opaque lotion base of purified water USP, white petrolatum USP, stearyl alcohol NF, propylene glycol USP, polysorbate 60 NF, cetyl alcohol NF, and benzoic acid USP 0.2% as a preservative. CLINICAL PHARMACOLOGY Pharmacokinetics: The penetration of oxiconazole nitrate into different layers of the skin was assessed using an in vitro permeation technique with human skin. Five hours after application of 2.5 mg/cm2 of oxiconazole nitrate cream onto human skin, the concentration of oxiconazole nitrate was demonstrated to be 16.2 µmol in the epidermis, 3.64 µmol in the upper corium, and 1.29 µmol in the deeper corium.
    [Show full text]
  • Topical Antifungals Used for Treatment of Seborrheic Dermatitis
    Journal of Bacteriology & Mycology: Open Access Review Article Open Access Topical antifungals used for treatment of seborrheic dermatitis Abstract Volume 4 Issue 1 - 2017 Seborrheic dermatitis is a common inflammatory condition mainly affecting scalp, Sundeep Chowdhry, Shikha Gupta, Paschal face and other seborrheic sites, characterized by a chronic relapsing course. The mainstay of treatment includes topical therapy comprising antifungals (ketoconazole, D’souza Department of Dermatology, ESI PGIMSR, India ciclopirox olamine) and anti-inflammatory agents along with providing symptomatic relief from itching. Oral antifungals and retinoids are indicated only in the severe, Correspondence: Sundeep Chowdhry, Senior Specialist and recalcitrant cases. The objective of this review is to discuss various topical antifungals Assistant Professor, Department of Dermatology, ESI PGIMSR, available for use in seborrheic dermatitis of scalp, face and flexural areas, discuss their Basaidarapur, New Delhi, India, Tel 919910084482, efficacy and safety profiles from relevant studies available in the literature along with Email [email protected] upcoming novel delivery methods to enhance the efficacy of these drugs. Received: October 28, 2016 | Published: January 06, 2017 Keywords: seborrheic dermatitis, antifungal agents, ketoconazole, ciclopirox Introduction Discussion Seborrheic dermatitis (SD) is a common, chronic inflammatory Treatment considerations disease that affects around 1-3% of the general population in many countries including the U.S., 3-5% of patients consisting of young Treatment for SD should aim for not just achieving remission of adults. The incidence of the disease has two peaks: one in newborn lesions but also to eliminate itching and burning sensation and prevent 6 infants up to three months of age, and the other in adults of around recurrence of the disease.
    [Show full text]
  • Application Number
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 205175Orig1s000 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 205-175 Priority or Standard Standard Submit Date(s) December 22, 2012 Received Date(s) December 24, 2012 PDUFA Goal Date October 24, 2013 Division / Office DDDP/ODE III Reviewer Name(s) Amy S. Woitach, D.O. Review Completion Date September 20, 2013 Established Name Econazole Nitrate Foam, 1% (Proposed) Trade Name Ecoza Therapeutic Class Antifungal Applicant Amderma Pharmaceuticals Formulation(s) Topical Foam Dosing Regimen Once daily for 4 weeks Indication(s) Interdigital tinea pedis Intended Population(s) Ages 12 years and older Template Version: March 6, 2009 Reference ID: 3376891 Clinical Review Amy S. Woitach, D.O. NDA 205-175 Econazole Nitrate Foam (Ecoza) 1% Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT......................................... 7 1.1 Recommendation on Regulatory Action ............................................................. 7 1.3 Recommendations for Postmarket Risk Evaluation and Mitigation Strategies ... 8 1.4 Recommendations for Postmarket Requirements and Commitments ................ 8 2 INTRODUCTION AND REGULATORY BACKGROUND ........................................ 9 2.1 Product Information .......................................................................................... 10 2.2 Tables of Currently Available Treatments for Tinea Pedis................................ 11 2.3 Availability of Proposed Active Ingredient in the United States
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]
  • Walgreens Plus Drug List
    Medication List Walgreens Plus™ members receive discounts on thousands of generic and brand-name medications included on this Medication List, which is divided into four sections: Value-Priced Generics, Brand-Name, Lifestyle and Discounted Medications.* Up to 85% off Cash Prices on Atorvastatin (generic Lipitor) and Rosuvastatin Up to (generic Crestor)* % Saving at Walgreens is easier off TM with Walgreens Plus , an 60 * exclusive program available Cash Prices at 17 select stores. With 20% off storewide every day,# discounts on eligible prescription purchases* and free prescription delivery,§ we’re adding more value to the Walgreens experience you already enjoy. * Savings apply only to prescriptions purchased by Walgreens Plus members from 17 select stores listed at Walgreens.com/Plus. Cannot be combined with any form of insurance or other pharmacy benefit programs. Actual savings will vary. # Only valid in a Walgreens store located in Florida or on Walgreens.com. Excludes prescriptions, clinic services, pharmacy items and services, sales tax, shipping and membership fees. Other restrictions apply. § Not available in all areas and excludes orders for perishable, age-restricted and other sensitive products as well as orders billed to Medicare Part B. Other restrictions and limitations apply. Learn more about the Walgreens Plus program at Walgreens.com/Plus. Table of contents Value-Priced Generics 3-12 Antifungal 3 Antiviral 3 Arthritis or Pain 3 Asthma 4 Blood Pressure/Heart Health 4-6 Cholesterol 6 Cough/Cold/Allergy 7 Diabetes 7-8 Ear
    [Show full text]